WallStreetZenWallStreetZen

NASDAQ: DSGN
Design Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for DSGN

Based on 1 analyst offering 12 month price targets for Design Therapeutics Inc.
Min Forecast
$4.00+44.4%
Avg Forecast
$4.00+44.4%
Max Forecast
$4.00+44.4%

Should I buy or sell DSGN stock?

Based on 1 analyst offering ratings for Design Therapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DSGN stock forecasts and price targets.

DSGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-14

1 of 1

Forecast return on equity

Is DSGN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.53%

Forecast return on assets

Is DSGN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

DSGN revenue forecast

What is DSGN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$48.5M
Avg 2 year Forecast
$117.3M
Avg 3 year Forecast
$204.8M

DSGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DSGN$2.77$4.00+44.40%Hold
IVA$3.69$18.00+387.80%Strong Buy
ZURA$3.55$10.00+181.69%Strong Buy
CRDF$3.49$7.00+100.57%Strong Buy
VOR$2.30$11.00+378.26%Buy

Design Therapeutics Stock Forecast FAQ

Is Design Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DSGN) stock is to Hold DSGN stock.

Out of 1 analyst, 0 (0%) are recommending DSGN as a Strong Buy, 0 (0%) are recommending DSGN as a Buy, 1 (100%) are recommending DSGN as a Hold, 0 (0%) are recommending DSGN as a Sell, and 0 (0%) are recommending DSGN as a Strong Sell.

If you're new to stock investing, here's how to buy Design Therapeutics stock.

What is DSGN's revenue growth forecast for 2025-2027?

(NASDAQ: DSGN) Design Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Design Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast DSGN's revenue for 2025 to be $2,717,776,672, with the lowest DSGN revenue forecast at $2,717,776,672, and the highest DSGN revenue forecast at $2,717,776,672. On average, 1 Wall Street analysts forecast DSGN's revenue for 2026 to be $6,570,713,721, with the lowest DSGN revenue forecast at $6,570,713,721, and the highest DSGN revenue forecast at $6,570,713,721.

In 2027, DSGN is forecast to generate $11,468,087,922 in revenue, with the lowest revenue forecast at $11,468,087,922 and the highest revenue forecast at $11,468,087,922.

What is DSGN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: DSGN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is DSGN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DSGN price target, the average DSGN price target is $4.00, with the highest DSGN stock price forecast at $4.00 and the lowest DSGN stock price forecast at $4.00.

The Wall Street analyst predicted that Design Therapeutics's share price could reach $4.00 by Nov 14, 2024. The average Design Therapeutics stock price prediction forecasts a potential upside of 44.4% from the current DSGN share price of $2.77.

What is DSGN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: DSGN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.